PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD)

This is an interventional treatment trial for Metastatic Colorectal Cancer focused on measuring colorectal cancer, marker-driven, bevacizumab, aflibercept, cytokines, angiogenic factors, CAF Read More

Inclusion Criteria:

• Patients with histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present)
• Patients with at least one measurable lesion, with size > 1 cm (RECIST v1.1)
• ECOG Performance status ≤ 2
• Life expectancy > 3 months
• Age ≥18 years.
• Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 100 x109/L, hemoglobin ≥ 9 g/dl or 5.59 mmol/l
• Patients not receiving therapeutic anticoagulation must have an INR < 1.5 and aPTT < 1.5 x ULN within 7 days prior to enrollment. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of enrollment.
• Adequate liver function as measured by serum transaminases (AST & ALT) ≤ 2.5 x ULN (in case of liver metastases < 5 x ULN) and total bilirubin ≤ 1.5 x ULN
• Adequate renal function: Serum creatinine ≤ 1.5 x ULN
• Signed, written informed consent
• At least 6 months after completion of adjuvant chemotherapy.

Exclusion Criteria:

• Treatment with any other investigational agent within 30 days prior to entering this study.
• Prior systemic or local treatment of metastatic disease.
• Prior adjuvant or neo-adjuvant chemotherapy/radiotherapy completed less than 6 months prior to study entry.
• Pre History or evidence upon physical/neurological examination of CNS disease (unrelated to cancer) (unless adequately treated with standard medical therapy) e.g. uncontrolled seizures.
• Fertile women (< 1 year after last menstruation) and men of childbearing potential unwilling or unable to use effective means of contraception (adequate: intrauterine device, long-acting injection, hormon implant, vasectomy) during treatment and for 6 months after the end of treatment.
• Pregnancy or lactation
• Positive serum pregnancy test within 7 days of starting study treatment in premenopausal women and women < 1 year after the onset of menopause.
• Past or current history (within the last 2 years prior to treatment start) of other malignancies except metastatic colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).
• Peripheral neuropathy NCI CTCAE-grade ≥ 1
• Known DPD-insufficiency.
• Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > 4 loose stools per day)
• History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) haemoptoe or evidence of interstitial lung disease on baseline CT scan.
• Serious, non-healing wound, ulcer or bone fracture.
• Thrombosis or severe bleeding within 6 months prior to entry into the study (except for bleeding of the tumor before its surgical resection) and no evidence of bleeding diathesis or coagulopathy.
• Urine dipstick for proteinuria ≥ 2+. If urine dipstick is ≥ 2+, 24-hour urine must demonstrate ≤ 1 g of protein in 24 hours for patient to be eligible.
• Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to treatment.
• Clinically significant cardiovascular disease, for example CVA, myocardial infarction (≤ 12 months before treatment start), unstable angina, NYHA Class II CHF, arrhythmia requiring medication, or uncontrolled hypertension.
• Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
• Known hypersensitivity or contraindication to the drugs used in the trial (eg: aflibercept, 5-FU, folinic acid/ leucovorin, oxaliplatin, bevacizumab, irinotecan).
• Concomitant treatment with ASS > 325 mg/d or NSAIDs, known to inhibit platelet function, sorivudin or analog compounds or preparations of St. John's wort.
• Inability or unwillingness to comply with the protocol.